MedPath

Losartan

Generic Name
Losartan
Brand Names
Hyzaar, Cozaar
Drug Type
Small Molecule
Chemical Formula
C22H23ClN6O
CAS Number
114798-26-4
Unique Ingredient Identifier
JMS50MPO89
Background

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication

Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions
Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke

FDA Approves First Liquid Losartan Formulation for Hypertension Treatment

• Scienture Holdings announced FDA approval of Arbli™ (losartan potassium) Oral Suspension, the first and only ready-to-use liquid losartan formulation in the U.S. market for treating hypertension in patients over 6 years old. • The novel formulation addresses significant unmet needs for patients requiring liquid medications, eliminating risks associated with crushing tablets and providing consistent dosing with an 18-month shelf life at room temperature. • Arbli™ is indicated for hypertension treatment, stroke risk reduction in patients with left ventricular hypertrophy, and diabetic nephropathy management, with commercial launch expected in Q3 2025.
© Copyright 2025. All Rights Reserved by MedPath